Longevity Biotech: The Next Revolution in Medicine
On September 30th, the eve of Global Longevity Day, I am hosting an invitation-only evening at Forbes House Madrid.
Presented by Trampoline Venture Partners (a private investment office) and sponsored by LongGame Capital (longevity venture capital firm) and Progevita (longevity clinic).
This intimate salon will give you the rare chance to engage in one-on-one conversations with:
Dr. Aubrey de Grey – world-renowned gerontologist and originator of Longevity Escape Velocity (LEV).
Sebastian Brunemeier – one of the earliest and most visionary venture capital investors in longevity biotech.
Jack Lowe – 83 years old, founder of the Fit for Life Foundation, investor, lifelong athlete, and author of the Fit for Life documentary.
We will explore the latest breakthroughs in:
Epigenetic reprogramming to reverse cellular aging.
Senolytics for clearing aging cells.
Advanced biomarker tracking for real-time health optimization.
Stem cell and tissue regeneration therapies.
Mitochondria transplants to restore cellular energy and function.
We are approaching Longevity Escape Velocity (LEV), a concept first developed by Aubrey de Grey, which describes the point at which science will extend human life faster than the pace at which we age (gaining >1 year per year).
This is also a unique networking opportunity to connect with experts and investors leading longevity innovation worldwide, including those linked to Yale, Stanford, Harvard, Oxford, and Cambridge.
--
Longevity biotech (LongBio) is the field of scientific research developing new medicines to slow and reverse the aging process.
Lifespan has been extended >50% in lab animals by multiple therapeutic interventions, preventing and reversing the damage of aging.
The next major revolution in medicine will be to target aging itself, which drives >90% of disease.
The event is hosted by Ignacio Garcia, a global venture investor and host of the Trampoline Zermatt Summit in the Swiss Alps, an annual meeting for startup investors and founders at the frontier of technology on the foothills of the Matterhorn.
Exclusively by invitation and for Forbes House members. Apply to attend.
Event Schedule:
18:00: Guest Cocktail Reception
Meet others interested in healthy aging, biohacking, and investing in the next generation of longevity pharmaceuticals.
18:30 Presentation by Aubrey de Grey, PhD
Founder of the LEV Foundation
One of the leading figures in the field of longevity biotech: explaining how the aging process really works and how to fix it, from an engineering perspective.
19:00 Presentation by Sebastian A. Brunemeier
Co-Founder and Partner at Long Game Ventures
One of the most prominent venture capitalists (VCs) and serial company founders in the longevity biotech field, speaking about therapeutic breakthroughs, the investment landscape, and potential that LongBio will become the largest and most impactful area of biopharma in our lifetimes.
19:30 Fireside chat: Q&A with the speakers
19:45 Presentation by Clara Fernández, Progēvita (Longevity Clinic owner)
Progēvita helps people who already care about their health reach their full longevity potential through precision medicine, offered in immersive programs at the largest longevity center in Europe.
20:00: Documentary Film Trailer & Discussion: "Dare to Dream"
Dare to Dream follows the inspiring story of Jack Lowe, at age 82, and three other cyclists over 50 as they take on a 300+ km ride through the French Alps. Their journey invites us to rethink what’s possible as we age - and celebrates the lifelong power of sport to fuel our health, connection, and sense of purpose.
Film trailer
20:15 Cocktail and networking
Speaker Bios:
Aubrey de Grey PhD, Founder of the LEV Foundation, author of Ending Aging, and the world’s most prominent proponent of rejuvenation biotech.
Dr. Aubrey de Grey is often regarded as the 'father of longevity biotech' — launching the field from the fringes of mad scientists to the hottest area in biopharma research with his groundbreaking book "Ending Aging" in 2007. He holds a PhD in Genetics from the University of Cambridge.
Sebastian Brunemeier, biotech VC and company builder focused on longevity & regenerative medicine.
Co-Founder and Partner at Long Game Ventures, General Partner at Healthspan Capital, co-founder and CIO of Cambrian Biopharma, Founder & COO of Samsara Therapeutics, Principal at Apollo Health Ventures.
Geroscientist by training (Oxford/Scripps PhD dropout as Clarendon Scholar, MSc in Molecular Neuro & Biotech Business Management). Link to selected presentations and podcasts.
Jack Lowe
Chairman of the Fit For Life Foundation in Switzerland
At 83 years old, this serial entrepreneur is the visionary founder of Fit For Life Foundation and a global advocate for healthy aging. His remarkable life journey serves as an inspiring testament to the principles he champions in the field of longevity. MBA from Stanford Business School, 37 years in private equity as CEO of Lomastar SA in Nyon Switzerland.
Clara Fernández Porta
CEO and owner of Progevita, RxLongevity, and Balneario Cofrentes, Clara Fernández Porta is a recognized leader in the longevity space—named among Spain’s Top 100 Female Leaders and Top 100 Creative Business Minds by Forbes España.
With a background from the University of Chicago Booth School of Business and a track record hosting leading events like Vitalism 2024 and the Longevity Biotech Fellowship #LBF4, Clara brings together global experts, investors, and policymakers to advance longevity science and innovation through immersive programs at Europe’s largest longevity center.
---
Note: There is a Madrid longevity conference in the following days International Longevity Summit (Oct 1–2, ICOMEM). More information: Madrid To Become the Longevity Capital of Europe.
Timeline of Longevity Biotech developments:
Sophisticated investors (Peter Thiel, Jeff Bezos, Sam Altman of OpenAI, Brian Armstrong of Coinbase) and firms (Novartis, Pfizer, Abbvie, ARCH Ventures, a16z, Lilly, Hevolution and the KSA) — longevity biotech is the next wave of pharmaceutical innovation.
For a summary of companies and players in the LongBio field, see the 2025 LongBio Report published by Sebastian Brunemeier and Healthspan Capital.
As covered by Forbes, Dr Michael Ringel, Managing Partner at consulting giant Boston Consulting Group (BCG), referred to the longevity biotech field as the single most impactful area for the future of the pharma industry.